MoonLake Immunotherapeutics (MLTX) Stock Overview
A clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MLTX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
MoonLake Immunotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.67 |
| 52 Week High | US$62.75 |
| 52 Week Low | US$5.95 |
| Beta | 1.24 |
| 1 Month Change | 33.09% |
| 3 Month Change | -76.75% |
| 1 Year Change | -76.61% |
| 3 Year Change | 39.54% |
| 5 Year Change | 21.83% |
| Change since IPO | 20.78% |
Recent News & Updates
Recent updates
Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?
Jul 26
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
Jun 03We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth
Apr 09MoonLake Immunotherapeutics: A Buy At Dips
Apr 08Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?
Jan 20We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate
Dec 16MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold
Oct 13MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Shareholder Returns
| MLTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | 1.1% | -1.3% |
| 1Y | -76.6% | 15.4% | 8.7% |
Return vs Industry: MLTX underperformed the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: MLTX underperformed the US Market which returned 8.7% over the past year.
Price Volatility
| MLTX volatility | |
|---|---|
| MLTX Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MLTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MLTX's weekly volatility has increased from 15% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 100 | Jorge da Silva | www.moonlaketx.com |
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics Fundamentals Summary
| MLTX fundamental statistics | |
|---|---|
| Market cap | US$904.30m |
| Earnings (TTM) | -US$210.50m |
| Revenue (TTM) | n/a |
Is MLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$210.50m |
| Earnings | -US$210.50m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 25.3% |
How did MLTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 08:39 |
| End of Day Share Price | 2025/11/21 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MoonLake Immunotherapeutics is covered by 19 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Samantha Lynn Semenkow | Citigroup Inc |